PURPOSE: Erythropoiesis stimulating agents (ESAs) are used to treat anemia in critically ill patients. This indication is off-label, because it is not licensed by regulatory authorities. Recently ESAs were suspected to harm critically ill patients. Our objective was to assess the safety of ESAs in off-label indications in critically ill patients. METHODS: Eleven databases were searched up to April 2012. We considered randomized controlled trials (RCTs) and controlled observational studies in any language that compared off-label ESAs treatment with other effective interventions, placebo or no treatment in critically ill patients. Two authors independently screened and evaluated retrieved records, extracted data and assessed risk of bias and quality of reporting. RESULTS: We used frequentist and Bayesian models to combine studies, and performed sensitivity and subgroup analyses. From 12,888 citations, we included 48 studies (34 RCTs; 14 observational), involving 944,856 participants. Harm reporting was of medium to low quality. There was no statistically significant increased risk of adverse events in general, serious adverse events, the most frequently reported adverse events, and death in critically ill patients treated with ESAs. These results were robust against risk of bias and analysis methods. There is evidence that ESAs increase the risk of clinically relevant thrombotic vascular events, and there is some less certain evidence that ESAs might increase the risk for venous thromboembolism. CONCLUSIONS: In critically ill patients, administration of ESAs is associated with a significant increase in clinically relevant thrombotic vascular events but not with other frequently reported adverse events and death.
PURPOSE: Erythropoiesis stimulating agents (ESAs) are used to treat anemia in critically illpatients. This indication is off-label, because it is not licensed by regulatory authorities. Recently ESAs were suspected to harm critically illpatients. Our objective was to assess the safety of ESAs in off-label indications in critically illpatients. METHODS: Eleven databases were searched up to April 2012. We considered randomized controlled trials (RCTs) and controlled observational studies in any language that compared off-label ESAs treatment with other effective interventions, placebo or no treatment in critically illpatients. Two authors independently screened and evaluated retrieved records, extracted data and assessed risk of bias and quality of reporting. RESULTS: We used frequentist and Bayesian models to combine studies, and performed sensitivity and subgroup analyses. From 12,888 citations, we included 48 studies (34 RCTs; 14 observational), involving 944,856 participants. Harm reporting was of medium to low quality. There was no statistically significant increased risk of adverse events in general, serious adverse events, the most frequently reported adverse events, and death in critically illpatients treated with ESAs. These results were robust against risk of bias and analysis methods. There is evidence that ESAs increase the risk of clinically relevant thrombotic vascular events, and there is some less certain evidence that ESAs might increase the risk for venous thromboembolism. CONCLUSIONS: In critically illpatients, administration of ESAs is associated with a significant increase in clinically relevant thrombotic vascular events but not with other frequently reported adverse events and death.
Authors: Michael Silver; Michael J Corwin; Andrea Bazan; Andrew Gettinger; Christopher Enny; Howard L Corwin Journal: Crit Care Med Date: 2006-09 Impact factor: 7.598
Authors: Erik Lipsic; Peter van der Meer; Adriaan A Voors; B Daan Westenbrink; Ad F M van den Heuvel; Hetty C de Boer; Anton J van Zonneveld; Regien G Schoemaker; Wiek H van Gilst; Felix Zijlstra; Dirk J van Veldhuisen Journal: Cardiovasc Drugs Ther Date: 2006-04 Impact factor: 3.727
Authors: Elie Azoulay; Giuseppe Citerio; Jan Bakker; Matteo Bassetti; Dominique Benoit; Maurizio Cecconi; J Randall Curtis; Glenn Hernandez; Margaret Herridge; Samir Jaber; Michael Joannidis; Laurent Papazian; Mark Peters; Pierre Singer; Martin Smith; Marcio Soares; Antoni Torres; Antoine Vieillard-Baron; Jean-François Timsit Journal: Intensive Care Med Date: 2014-01-24 Impact factor: 17.440
Authors: Susanne Schmitz; Tatjana T Makovski; Roisin Adams; Marjan van den Akker; Saverio Stranges; Maurice P Zeegers Journal: Pharmacoeconomics Date: 2020-01 Impact factor: 4.981
Authors: Pablo García-Olivares; Jose Eugenio Guerrero; Pedro Galdos; Demetrio Carriedo; Francisco Murillo; Antonio Rivera Journal: Intensive Care Med Date: 2014-08-20 Impact factor: 17.440